Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
70.10
+0.60 (0.86%)
Nov 13, 2026, 1:30 PM CST

TPE:6919 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-611.32-351.92-588.83-488.46-286.16-224.29
Depreciation & Amortization
28.8430.6629.5127.8725.3423.28
Loss (Gain) From Sale of Assets
----0.11-
Stock-Based Compensation
283.59122.165.0522.9819.7174.76
Other Operating Activities
-152.5-187.28-6.69-0.35-0.36-3.27
Change in Accounts Receivable
2.89-1.312.71-4.77-3.12-
Change in Inventory
-0.57-0.02-1.841.78-2.762.48
Change in Accounts Payable
-0.520.29-0.73-0.832.21-0.41
Change in Unearned Revenue
7.03-2.542.59-3.474.5-
Change in Other Net Operating Assets
45.55-35.88-24.0821.32-2.2216.77
Operating Cash Flow
-397.01-425.9-522.31-423.94-242.76-110.7
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-17.55-16.53-10-8.6-14.16-14.9
Sale of Property, Plant & Equipment
----0-
Sale (Purchase) of Intangibles
-0.67-0.61-1.09-1.09--
Investment in Securities
889.49-5,603-2,478166.78-456.18-
Other Investing Activities
-13.49-4.61-0.01-0.2-
Investing Cash Flow
857.79-5,624-2,489157.09-470.54-14.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt Issued
125-----
Long-Term Debt Repaid
--8.88-8.58-8.22-12.6-93.98
Lease Payments
-9.03-8.88-8.58-8.22-7.87-6.79
Total Debt Repaid
-9.03-8.88-8.58-8.22-12.6-93.98
Net Debt Issued (Repaid)
115.97-8.88-8.58-8.22-12.6-93.98
Issuance of Common Stock
35.1544.296,4993,042784.32720.88
Repurchase of Common Stock
-154.52-154.52----0.09
Financing Cash Flow
39.51-119.116,4913,034771.72626.81

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
24.6252.24-0.110.321.730.14
Net Cash Flow
524.92-6,1173,4792,76760.15501.35

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-414.55-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Growth
------
Free Cash Flow Margin
-2594.50%-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%
Free Cash Flow Per Share
-0.27-0.29-0.37-0.35-0.22-0.14
Levered Free Cash Flow
-534.71-401.63-391.26-266.4-171.06-74
Unlevered Free Cash Flow
-533.89-401.53-391.05-266.09-170.65-72.19
Free Cash Flow After Leases
-423.58-451.31-540.89-440.76-264.8-132.39

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.160.160.330.50.676.18
Cash Income Tax Paid
-----0.03
Change in Working Capital
54.39-39.46-21.3514.03-1.418.84